Press Release: Neurodyn’s Phase 1A
Neurodyn, the Charlottetown startup working on treatments for neurological diseases, has issued the following press release:
Positive Phase 1a outcome for Memogain
Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain’s potential benefits over existing Alzheimer’s drugs;
• increased safety in the absence of significant side effects,
• more potent cognitive enhancement.
The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered Memogain in healthy young